Clinical trialUNITERAREApr 9
Researchers are testing a new medicine called difelikefalin to see if it's safe and works well for teenagers on kidney dialysis who have severe itching. Itching is a common problem for dialysis patients that can really affect their quality of life. This study will check whether the medicine helps reduce itching and what side effects it might cause.
WHY IT MATTERSThis is the first trial testing difelikefalin specifically in adolescents on hemodialysis with moderate-to-severe pruritus — a condition that significantly impacts quality of life but has limited treatment options for younger patients.
Clinical trialCLINICALTRIALSApr 6
Researchers are testing a new drug called zipalertinib to see if it helps people with early-stage lung cancer that has specific genetic mutations. Patients who had surgery to remove their tumors will receive either the new drug or a placebo (fake medicine) along with standard chemotherapy. The study wants to find out if zipalertinib can prevent the cancer from coming back better than chemotherapy alone.
WHY IT MATTERSIf you have early-stage NSCLC with uncommon EGFR mutations (like exon 20 insertions) and recently had surgery, this trial offers access to a targeted therapy specifically designed for your mutation type before it becomes widely available.
Clinical trialUNITERAREApr 5
Researchers are looking for people with Down syndrome (Trisomy 21) to join a study about how their immune system works differently and ages over time. Some participants will have had their thymus gland removed, while others won't have, so scientists can compare how this affects immune health. The study will help doctors understand why people with Down syndrome often get more infections and have other immune-related health problems.
WHY IT MATTERSThis trial is now recruiting people with Down syndrome to help researchers understand immune system problems that affect this population — findings could lead to better treatments for infections and other immune conditions common in Trisomy 21.
Clinical trialUNITERAREApr 5
Researchers are testing a new drug called ManNAc to treat primary focal segmental glomerulosclerosis (FSGS), a rare kidney disease that causes scarring and can lead to kidney failure. This is a Phase 2 trial, meaning the drug has already been tested for safety in a small group and now researchers want to see if it actually works to help patients. The trial is now accepting patients and is expected to start in April 2026.
WHY IT MATTERSThis trial offers patients with primary FSGS access to an investigational treatment that may slow or stop kidney damage, with enrollment now open at sites participating in the National Human Genome Research Institute study.
Clinical trialUNITERAREApr 5
Researchers are testing a new drug called CYT107 to help people with HIV who have Kaposi Sarcoma (a type of cancer) and whose immune systems aren't responding well to treatment. CYT107 is designed to boost the immune system to help fight the cancer. This is a Phase 2 trial, meaning it's testing whether the drug works and is safe in a larger group of people. The trial is now accepting patients and will start in April 2026.
WHY IT MATTERSThis trial offers a potential new treatment option for people with HIV-related Kaposi Sarcoma who haven't responded to standard immune-boosting treatments, addressing a significant gap in care for this vulnerable population.
Clinical trialUNITERAREApr 5
Researchers are testing a new tool called the Esophageal String Test to help diagnose eosinophilic esophagitis, a condition where too many white blood cells build up in the food pipe and cause trouble swallowing. The test uses a small string that you swallow to collect samples from your esophagus. This study is enrolling people in Mali and the United States who have difficulty swallowing.
WHY IT MATTERSThis trial offers a potentially simpler, non-invasive screening method for eosinophilic esophagitis that could reduce the need for traditional endoscopy procedures, particularly for underserved populations in Africa and the US.
Clinical trialUNITERAREApr 3
Researchers at the University of Alabama at Birmingham are looking for premature babies to join a study about pulmonary hypertension—a condition where blood pressure in the lungs gets too high. The study will test different oxygen level targets to see which approach helps prevent or reduce lung problems in preterm infants. This trial is now actively recruiting participants and is expected to start in April 2026.
WHY IT MATTERSThis trial directly addresses a common complication in premature infants where improper oxygen management can cause lasting lung damage, making oxygen saturation targeting strategies critical for improving long-term outcomes in this vulnerable population.
Clinical trialUNITERAREApr 3
Researchers at St. Jude Children's Research Hospital are looking for people with sickle cell disease to participate in a study about egg health and fertility. The study will examine how sickle cell disease affects the ovaries and a woman's ability to have children. This research could help doctors better understand and protect fertility in women with sickle cell disease.
WHY IT MATTERSThis trial is now recruiting patients with sickle cell disease to understand how the disease affects ovarian function and fertility — information that could lead to better fertility preservation strategies for affected women.
Clinical trialUNITERAREApr 3
Researchers are testing a new treatment approach for elderly patients with a type of blood cancer (MDS or AML) that has come back or stopped responding to previous treatments. The study uses a combination of chemotherapy drugs followed by a stem cell transplant from a donor to try to help patients recover. This trial is now actively looking for patients to participate.
WHY IT MATTERSThis trial offers elderly patients with relapsed or refractory MDS/AML a potentially less toxic conditioning regimen before stem cell transplant — cladribine-bridged LABU may improve tolerability compared to standard high-dose approaches in this vulnerable population.
Clinical trialCLINICALTRIALSApr 3
Researchers are looking for 100 people with rare types of joint inflammation to better understand how these conditions develop and damage joints. Some of these inflammatory arthritides occur alongside rare autoimmune diseases like systemic sclerosis, while others develop as side effects from cancer immunotherapy drugs. By studying tissue samples and immune cells from patients, scientists hope to discover why these conditions happen and potentially develop better treatments.
WHY IT MATTERSIf you have rare inflammatory arthritis, systemic sclerosis with joint involvement, or developed joint inflammation after cancer immunotherapy, this trial could help researchers understand your condition better and may lead to more targeted treatments in the future.
Clinical trialUNITERAREApr 3
Researchers are testing a new technology called 'digital twins' to help prevent second strokes in patients with three rare brain conditions: moyamoya disease, cerebral amyloid angiopathy, and previous stroke history. A digital twin is a computer model of a patient's brain that doctors can use to predict what treatments might work best for that individual. This study will randomly assign patients to either receive care guided by this digital twin technology or standard care, and compare which approach prevents more strokes.
WHY IT MATTERSThis trial offers patients with moyamoya disease or cerebral amyloid angiopathy who have had a stroke access to personalized, AI-guided prevention strategies that could reduce their risk of future strokes.
Clinical trialUNITERAREApr 3
Researchers at St. Jude Children's Research Hospital are testing a drug called entrectinib to treat very young children (under 3 years old) who have brain or spinal cord tumors caused by changes in specific genes called NTRK1, NTRK2, NTRK3, or ROS1. This is a Phase 2 trial, meaning they've already tested the drug in a small group and now want to see if it works well in more patients. The trial is now accepting new patients and is expected to start in April 2026.
WHY IT MATTERSThis trial offers a targeted treatment option specifically designed for infants and toddlers with NTRK- or ROS1-fused CNS tumors, a group that has historically had very limited treatment options and poor outcomes.
Clinical trialUNITERAREApr 3
Researchers are looking for patients with a specific type of brain cancer called glioblastoma (GBM) to test a new drug combination. The study will test a drug called silevertinib combined with temozolomide in patients whose tumors have certain genetic features (unmethylated MGMT and EGFRvIII). This is an early-stage study to see if this combination works better than current treatments.
WHY IT MATTERSThis trial targets newly diagnosed GBM patients with unmethylated MGMT and EGFRvIII mutations—a subgroup with historically poor prognosis—and offers access to a potentially more effective treatment combination before it becomes widely available.
Clinical trialUNITERAREApr 3
Researchers are looking for African American cancer survivors to join a study about genetic testing. The study will test a new approach designed specifically for African American communities to help more people get tested for inherited cancer genes. Genetic testing can show if someone has genes that increase cancer risk, which helps with prevention and treatment planning.
WHY IT MATTERSThis trial addresses a critical gap: African American cancer survivors are significantly underrepresented in genetic testing programs, meaning many miss opportunities for personalized cancer prevention and family screening.
Clinical trialUNITERAREApr 3
Researchers at the University of Alberta are looking for participants for a study about preventing a serious lung infection called VAP (ventilator-associated pneumonia) in newborn babies. This infection happens when babies on breathing machines in the hospital develop pneumonia. The study will track cases across the country and test ways to stop this infection from happening.
WHY IT MATTERSIf your newborn is in a neonatal intensive care unit (NICU) on a ventilator, this trial could help identify prevention strategies that reduce the risk of developing a serious secondary infection during their hospital stay.
Clinical trialUNITERAREApr 3
Researchers are testing a new drug called Xaluritamig to treat Ewing sarcoma, a rare bone cancer that has come back or stopped responding to previous treatments. This is an early-stage study (Phase 1) that will include children, teenagers, and adults. The study is now accepting patients and is expected to start in April 2026.
WHY IT MATTERSThis trial offers a potential new treatment option for patients with relapsed or refractory Ewing sarcoma, a rare pediatric cancer with limited treatment alternatives after standard therapies fail.
Clinical trialUNITERAREApr 3
Lumos Pharma is testing a new drug called LUM-201 in children who don't produce enough growth hormone naturally. This Phase 3 trial is the final stage of testing before the drug might be approved by the FDA. Researchers are actively recruiting children to participate and see if this treatment helps them grow taller.
WHY IT MATTERSThis is now actively recruiting children with growth hormone deficiency — families interested in potentially accessing LUM-201 before FDA approval should check eligibility requirements and contact the trial sites listed on ClinicalTrials.gov.
Clinical trialUNITERAREApr 3
Researchers are looking for patients with a type of blood cancer called acute lymphoblastic leukemia (ALL) to test a new treatment combination. The study will test whether adding a drug called JZP458 to standard chemotherapy works better than chemotherapy alone. This trial is just starting and will recruit patients beginning in April 2026.
WHY IT MATTERSThis Phase 2 trial is now actively recruiting newly diagnosed ALL patients without the Philadelphia chromosome, offering access to an investigational asparaginase formulation (JZP458) that may have improved tolerability compared to standard asparaginase.
Clinical trialUNITERAREApr 3
This is a clinical trial testing a blood clotting medicine called Nuwiq in women and girls with hemophilia A who need surgery. Hemophilia A is a rare bleeding disorder where the body doesn't make enough of a protein that helps blood clot. The trial will study how well Nuwiq works and what dose is best for these patients during surgical procedures.
WHY IT MATTERSThis trial is specifically designed for women and girls with hemophilia A undergoing surgery — a population that often receives less research attention than males with the same condition.
Clinical trialUNITERAREApr 3
Triple Hair Inc is recruiting patients for a Phase 3 clinical trial testing a new treatment called TH07 for androgenic alopecia, commonly known as male or female pattern baldness. This is a large-scale study to confirm whether TH07 works better than current treatments. If you have pattern hair loss, you may be eligible to join and help test this potential new therapy.
WHY IT MATTERSThis Phase 3 trial is actively recruiting now, meaning if you have androgenic alopecia, you could potentially enroll and access an investigational treatment while contributing to evidence that could lead to FDA approval.